Clinical Trial Update: An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients [Phase 3]

View source ↗

Summary

This records the completion of an open-label safety extension of SLV308 in early-stage Parkinson's disease within a Phase 3 program.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SLV308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Early Stage Parkinson's Disease | Phase 3 | Status: COMPLETED